⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

Official Title: An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Study ID: NCT04223856

Study Description

Brief Summary: This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have cancer that has spread from their urinary system to other parts of their body.

Detailed Description: Japan PMDA has approved enfortumab vedotin (Padcev) for the treatment of advanced urothelial cancer. The study will continue as a post marketing study in Japan. This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab versus standard of care gemcitabine + platinum-containing chemotherapy, in subjects with previously untreated locally advanced or metastatic urothelial cancer. Enfortumab vedotin may be administered for an unlimited number of cycles until a protocol defined reason for study discontinuation occurs. Pembrolizumab may be administered for a maximum of 35 cycles or a protocol-defined reason for study discontinuation occurs, whichever is first. Cisplatin or carboplatin plus gemcitabine may be administered for a maximum of 6 cycles or a protocol-defined reason for study discontinuation occurs, whichever is first.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Ironwood Cancer & Research Centers - Chandler, Chandler, Arizona, United States

Arizona Oncology Associates PD - HOPE, Tucson, Arizona, United States

Providence St Joseph Medical Center, Burbank, California, United States

City of Hope National Medical Center, Duarte, California, United States

University of California Los Angeles Medical Center, Los Angeles, California, United States

University of California Irvine - Newport, Orange, California, United States

Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States

University of Colorado Hospital / University of Colorado, Aurora, Colorado, United States

Cancer Centers of Colorado - Denver, Denver, Colorado, United States

Yale Cancer Center, New Haven, Connecticut, United States

Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States

Lombardi Cancer Center / Georgetown University Medical Center, Washington, District of Columbia, United States

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States

Georgia Cancer Specialists / Northside Hospital Cancer Institute, Marietta, Georgia, United States

Louisiana State University/ East Jefferson General Hospital, Metairie, Louisiana, United States

Maine Health Cancer Care, Biddeford, Maine, United States

Johns Hopkins Medical Center, Baltimore, Maryland, United States

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States

New Mexico Cancer Center, Albuquerque, New Mexico, United States

New York University (NYU) Cancer Institute, New York, New York, United States

Mount Sinai Medical Center, New York, New York, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Vidant Medical Center, Greenville, North Carolina, United States

The Cleveland Clinic, Cleveland, Ohio, United States

Toledo Clinic Cancer Center, Toledo, Ohio, United States

Hillman Cancer Center / University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Saint Francis Hospital / Bon Secours - South Carolina, Greenville, South Carolina, United States

West Cancer Center & Research Institute, Germantown, Tennessee, United States

University of Texas Southwestern Medical Center, Dallas, Texas, United States

UT Health East Texas Hope Cancer Center, Tyler, Texas, United States

Huntsman Cancer Institute, Salt Lake City, Utah, United States

University of Virginia, Charlottesville, Virginia, United States

Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, United States

Site AR54008, Buenos Aire, , Argentina

Site AR54011, Caba, , Argentina

Site AR54005, Cordoba, , Argentina

Site AR54006, La Rioja, , Argentina

Site AR54004, Mendoza, , Argentina

Site AR54001, Rosario, , Argentina

Site AR54002, San Miguel, , Argentina

Site AR54012, Tucuman, , Argentina

Site AR54003, Viedma, , Argentina

Site AU61003, Box Hill, , Australia

Site AUS61001, Douglas, , Australia

Site AUS61004, Heidelberg, , Australia

Site AUS61002, Macquarie Park, , Australia

Site AUS61006, South Australia, , Australia

Site AU61005, South Brisbane, , Australia

Site BE32003, Brussels, , Belgium

Site BE32002, Ghent, , Belgium

Site BE32001, Liege, , Belgium

Site BE32007, Lueven, , Belgium

Site BE32006, Roeselare, , Belgium

Site CA11004, Calgary, Alberta, Canada

Site CA11003, Edmonton, Alberta, Canada

Site CA11006, Vancouver, British Columbia, Canada

Site CA11002, Hamilton, Ontario, Canada

Site CA11009, London, Ontario, Canada

Site CA11011, Oshawa, Ontario, Canada

Site CA11012, Toronto, Ontario, Canada

Site CA11005, Toronto, Ontario, Canada

Site CA11010, Montreal, Quebec, Canada

Site CA11001, Montreal, Quebec, Canada

Site CA11008, Quebec, , Canada

Site CN86009, Beijing City, , China

Site CN86001, Beijing, , China

Site CN86004, Beijing, , China

Site CN86005, Beijing, , China

Site CN86015, Bengbu, , China

Site CN86003, Changchun, , China

Site CN86006, Changsha, , China

Site CN86016, Changsha, , China

Site CN86010, Chengdu, , China

Site CN86024, Chongqing, , China

Site CN86007, Chongqing, , China

Site CN86028, Fuzhou, , China

Site CN86002, Guangzhou, , China

Site CN86020, Gunagzhou, , China

Site CN86018, Hangzhou, , China

Site CN86013, Hangzhou, , China

Site CN86022, Hangzhou, , China

Site CN86025, Hefei, , China

Site CN86027, Jinan, , China

Site CN86017, Nanjing, , China

Site CN86012, Nanjing, , China

Site CN86021, Ningbo, , China

Site CN86014, Shanghai, , China

Site CN86011, Shenyang City, , China

Site CN86023, Tianjin, , China

Site CN86019, Tianjin, , China

Site CN86029, Wenzhou, , China

Site CN86008, Wuhan City, , China

Site CN86030, Xicheng District, , China

Site CN86026, Xuzhou, , China

Site CZ42006, Brno, , Czechia

Site CZ42001, Hradec Kralove, , Czechia

Site CZ42004, Olomouc, , Czechia

Site CZ42005, Praha 4-Krc, , Czechia

Site DK45001, Aalborg, , Denmark

Site DK45003, Aarhus N, , Denmark

Site FR33014, Bordeaux, , France

Site FR33016, Lyon, , France

Site FR33003, Nice Cedex 2, , France

Site FR33020, Pierre-Bénite, , France

Site FR33013, Strasbourg, , France

Site FR33017, TOURS Cedex 09, , France

Site FR33011, Villejuif-Cedex-France, , France

Site DE49003, Berlin, , Germany

Site DE49013, Bielefeld, , Germany

Site DE49016, Düsseldorf, , Germany

Site DE49014, Erlangen, , Germany

Site DE49011, Essen, , Germany

Site DE49007, Frankfurt am Main, , Germany

Site DE49015, Gottingen, , Germany

Site DE49005, Heidelberg, , Germany

Site DE49009, Herne, , Germany

Site DE49006, Jena, , Germany

Site DE49001, Lubeck, , Germany

Site DE49008, Magdeburg, , Germany

Site DE49012, Mannheim, , Germany

Site DE49002, Munchen, , Germany

Site DE49004, Tübingen, , Germany

Site DE49010, Ulm, , Germany

Site HU36003, Budapest, , Hungary

Site HU36002, Budapest, , Hungary

Site HU36006, Debrecen, , Hungary

Site HU36001, Nyiregyhaza, , Hungary

Site HU36005, Szolnok, , Hungary

Site IL97203, Beer Sheva, , Israel

Site IL97201, Haifa, , Israel

Site IL97209, Holon, , Israel

Site IL97206, Jerusalem, , Israel

Site IL97202, Kfar Saba, , Israel

Site IL97208, Petach Tikva, , Israel

Site IL97211, Rehovot, , Israel

Site IL97210, Tel Aviv, , Israel

Site IL97204, Tel Hashomer, , Israel

Site IL97205, Zerifin, , Israel

Site IT39005, Areezo, , Italy

Site IT39008, Candiolo, , Italy

Site IT39009, Cremona, , Italy

Site IT39006, Genova, , Italy

Site IT39003, Meldola, , Italy

Site IT39014, Milano, , Italy

Site IT39007, Milano, , Italy

Site IT39004, Pisa, , Italy

Site IT39002, Terni, , Italy

Site IT39011, Torrette, , Italy

Site IT39001, Verona, , Italy

Site JP81002, Bunkyo City, , Japan

Site JP81009, Chiba, , Japan

Site JP81018, Chiba, , Japan

Site JP81013, Fukuoka, , Japan

Site JP81020, Fukuoka, , Japan

Site JP81011, Hirosaki, , Japan

Site JP81006, Kawasaki-shi, , Japan

Site JP81001, Koto-ku, , Japan

Site JP81017, Kyoto, , Japan

Site JP81015, Niigata, , Japan

Site JP81005, Okayama, , Japan

Site JP81016, Osakasayama-Shi, , Japan

Site JP81008, Osaka, , Japan

Site JP81007, Sapporo, , Japan

Site JP81012, Sendai-city, , Japan

Site JP81014, Tokushima, , Japan

Site JP81019, Tokyo, , Japan

Site JP81003, Toyama, , Japan

Site JP81004, Tsukuba, , Japan

Site JP81010, Ube, , Japan

Site KR82001, Daejeon, , Korea, Republic of

Site KR82002, Goyang-si, , Korea, Republic of

Site KR82008, Hwasun, , Korea, Republic of

Site KR82004, Seongnam-si, , Korea, Republic of

Site KR82003, Seoul, , Korea, Republic of

Site KR82005, Seoul, , Korea, Republic of

Site KR82007, Seoul, , Korea, Republic of

Site KR82006, Seoul, , Korea, Republic of

Site NL31005, Amsterdam, Noord-Holland, , Netherlands

Site NL31002, Amsterdam, , Netherlands

Site NL31001, Amsterdam, , Netherlands

Site NL31007, Leeuwarden, , Netherlands

Site NL31004, Nieuwegein, , Netherlands

Site NL31003, Rotterdam, , Netherlands

Site NL31006, Utrecht, , Netherlands

Site PL48002, Warszawa, , Poland

Site RU70016, Arkhangelsk, , Russian Federation

Site RU70013, Barnaul, , Russian Federation

Site RU70020, Ivanovo, , Russian Federation

Site RU70014, Krasnoyarsk, , Russian Federation

Site RU70006, Leningradskaya Oblast', , Russian Federation

Site RU70004, Moscow, , Russian Federation

Site RU70011, Moscow, , Russian Federation

Site RU70003, Moscow, , Russian Federation

Site RU70017, Nizhniy Novgorod, , Russian Federation

Site RU70002, Omsk, , Russian Federation

Site RU70019, Pyatigorsk, , Russian Federation

Site RU70010, Saint Petersburg, , Russian Federation

Site RU70007, Saint Petersburg, , Russian Federation

Site RU70012, Saint-Petersburg, , Russian Federation

Site RU70009, Saransk, , Russian Federation

Site RU70008, St. Petersburg, , Russian Federation

Site RU70015, Tyumen, , Russian Federation

Site RU70005, Ufa, , Russian Federation

Site SG65001, Singapore, , Singapore

Site SG65002, Singapore, , Singapore

Site SG65003, Singapore, , Singapore

Site ES34017, Barcelona, , Spain

Site ES34010, Barcelona, , Spain

Site ES34006, Barcelona, , Spain

Site ES34001, Barcelona, , Spain

Site ES34008, Barcelona, , Spain

Site ES34013, Cordoba, , Spain

Site ES34021, Lugo, , Spain

Site ES34018, Madrid, , Spain

Site ES34002, Madrid, , Spain

Site ES34003, Madrid, , Spain

Site ES34015, Madrid, , Spain

Site ES34004, Manresa, , Spain

Site ES34020, Pamplona, , Spain

Site ES34016, Sabadell, , Spain

Site ES34012, Santander, , Spain

Site ES34007, Sevilla, , Spain

Site ES34019, Valencia, , Spain

Site ES34009, Valencia, , Spain

Site CH41004, Basel, , Switzerland

Site CH41002, Bern, , Switzerland

Site CH41001, Chur, , Switzerland

Site CH41003, Winterthur, , Switzerland

Site TW88603, Kaohsiung, , Taiwan

Site TW88602, Kweishan, , Taiwan

Site TW88607, Taichung, , Taiwan

Site TW88606, Taichung, , Taiwan

Site TW88604, Tainan, , Taiwan

Site TW88605, Taipei, , Taiwan

Site TW88601, Taipei, , Taiwan

Site TH66004, Bangkok, , Thailand

Site TH66003, Bangkok, , Thailand

Site TH66005, Chiang Mai, , Thailand

Site TH66002, HatYai, , Thailand

Site TH66006, Krung Thep Maha Nakhon, , Thailand

Site TH66007, Muang, , Thailand

Site TH66001, Ratchathewi, , Thailand

Site TR90007, Ankara, , Turkey

Site TR90009, Ankara, , Turkey

Site TR90005, Antalya, , Turkey

Site TR90004, Edirne, , Turkey

Site TR90008, Istanbul, , Turkey

Site TR90003, Istanbul, , Turkey

Site TR90002, Istanbul, , Turkey

Site TR90001, Konya, , Turkey

Site TR90006, Malatya, , Turkey

Site UK44005, Glasgow, , United Kingdom

Site UK44001, London, , United Kingdom

Site UK44009, London, , United Kingdom

Site UK44006, Oxford, , United Kingdom

Site UK44010, Plymouth, , United Kingdom

Site UK44002, Preston, , United Kingdom

Site UK44003, Sheffield, , United Kingdom

Site UK44008, Southampton, , United Kingdom

Contact Details

Name: Zejing Wang, MD, PhD

Affiliation: Seagen Inc.

Role: STUDY_DIRECTOR

Name: John Lu, MD

Affiliation: Seagen Inc.

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: